The drug, with the unwieldy name ceftolozane / tazobactam, has completed Phase 3 clinical trials and could prove particularly effective in dealing
with pseudomonas — bacteria usually acquired in hospitals that cause serious interabdominal and urinary tract infections, ultimately resulting in death in some cases.
Personally, I believe it has something to do
with the lactoferrin it contains, as lactoferrin is supposedly something that can penetrate the bio film of
pseudomonas.